Big Medtech’s interest in urology deepens as Boston bags AMS men’s health biz
This article was originally published in Clinica
Executive Summary
Not long after rival Medtronic made an acquisition in the urology sector, Boston Scientific has followed suit, agreeing to buy American Medical Systems’ urology portfolio from Endo International. The deal is worth $1.6bn upfront and up to $50m in milestone payments.
You may also be interested in...
Boston Scientific Invests In Urology With $600M Augmenix Acquisition
Augmenix is the privately-held developer of SpaceOAR, an injected hydrogel spacer that is indicated for reducing collateral damage from radiation treatment for prostate cancer. It addresses a market worth about $750m, with total sales expected to reach $90m in 2019.
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.